FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

			or Section 30(n) or the investment Company Act or 1940				
1. Name and Address of Reporting Person* <u>Desai Antal Rohit</u>			2. Issuer Name and Ticker or Trading Symbol PROCEPT BioRobotics Corp [ PRCT ]		tionship of Reporting Per all applicable) Director X		on(s) to Issuer
(Last) C/O PROCEPT 900 ISLAND D		(Middle) CORPORATION	3. Date of Earliest Transaction (Month/Day/Year) 09/06/2022	_	Officer (give title below)		Other (specify below)
(Street) REDWOOD CITY (City)	CA (State)	94065 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Form filed by One Form filed by Mor Person	Repo	rting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	09/06/2022		J <sup>(2)</sup>		743,021	D	\$0	10,075,491(2)	I	By White Tailed Ptarmigan, LP <sup>(1)</sup>		
Common Stock								5,790(3)	I	By Kestrel Fund, L.P.		
Common Stock								36,924(3)	I	By Mallard Fund, L.P.		
Common Stock								57,809(3)	I	By The 2:22 DNA Trust <sup>(4)</sup>		
Common Stock								54,641	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	th/Day/Year)   Execution Date, if any (Month/Day/Year)   (Month/Day/Year)   Transaction Code (Instr. 8)   Secu Acqu (A) o Disp of (D (Instr. 9))		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr	rative rities ired r osed )	Expiration Date (Month/Day/Year)			e and unt of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## **Explanation of Responses:**

- 1. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Kent McGaughy, Jr., CPMG, Inc. and White Tailed Ptarmigan, LP jointly report their beneficial ownership of these shares on a separate Form 4.
- 2. On September 6, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 99,881 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13
- 3. Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on September 6, 2022, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.
- 4. Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by The 2:22 DNA Trust except to the extent of any pecuniary interest therein.

/s/ Antal Rohit Desai

09/08/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.